Analyst Price Target is $48.20
▲ +270.77% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Vor Biopharma in the last 3 months. The average price target is $48.20, with a high forecast of $60.00 and a low forecast of $19.00. The average price target represents a 270.77% upside from the last price of $13.00.
Current Consensus is
The current consensus among 5 polled investment analysts is to buy stock in Vor Biopharma.
Vor Biopharma, Inc., early-stage cell therapy company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.